^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KFA115

    i
    Other names: NVPKFA115, KFA115, NVP-KFA115, KFA 115, NVP KFA115, KFA-115
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 126
    Enrollment closed • Enrollment change
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    MSI-H/dMMR • BRAF mutation • BRCA mutation
    |
    Keytruda (pembrolizumab) • KFA115
    11ms
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=180, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2026 --> Sep 2027 | Trial primary completion date: Feb 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • KFA115
    over2years
    A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=220, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2025 --> Feb 2026 | Trial primary completion date: Sep 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • KFA115
    over3years
    A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=220, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • KFA115
    over3years
    A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=220, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • KFA115